Results 301 to 310 of about 322,587 (327)
Some of the next articles are maybe not open access.
Update on angiogenesis inhibitors
Current Opinion in Oncology, 2005A number of therapeutic agents have been developed which have anti-angiogenic potential. Here we present the most recent data from clinical trials with some of the promising inhibitors of angiogenesis.Agents that target the vascular endothelial growth factor signaling pathway are the furthest along in clinical development.
Anaadriana, Zakarija, Gerald, Soff
openaire +2 more sources
Endogenous angiogenesis inhibitors
APMIS, 2004When the FDA commissioner announced in February 2004 the approval of Avastin for the treatment of patients with colon cancer, he called angiogenesis inhibitors a fourth modality of anti‐cancer therapy. Because angiogenesis inhibitors are relatively less toxic than conventional chemotherapy and have a lower risk of drug resistance, they may also ...
openaire +2 more sources
Endogenous Inhibitors of Angiogenesis
Cancer Research, 2005Abstract Angiogenesis, the formation of new blood vessels, is required for many pathologic processes, including invasive tumor growth as well as physiologic organ/tissue maintenance. Angiogenesis during development and adulthood is likely regulated by a balance between endogenous proangiogenic and antiangiogenic factors. It is speculated
Pia, Nyberg, Liang, Xie, Raghu, Kalluri
openaire +2 more sources
Heparin Derivatives as Angiogenesis Inhibitors
Current Pharmaceutical Design, 2003Angiogenesis is the process of generating new capillary blood vessels. Uncontrolled endothelial cell proliferation is observed in tumor neovascularization and in angioproliferative diseases. Tumors cannot growth as a mass above few mm(3) unless a new blood supply is induced. It derives that the control of the neovascularization process may affect tumor
PRESTA, Marco +8 more
openaire +2 more sources
Inhibitors of Tumor Angiogenesis
2008Inhibitors of Tumor ...
Harris, Adrian L, GENERALI, DANIELE
openaire +3 more sources
Angiogenesis Inhibitors May Regulate Adiposity
Nutrition Reviews, 2003Overweight and obese are major health concerns owing to the complex co-morbidities that inevitably follow. Diet and exercise are the primary means by which people attempt to lose weight. A recent study in an obese mouse model suggested that angiogenesis inhibitors, which are designed to inhibit tumor growth, are able to reduce adipose tissue mass by ...
Liping, Liu, Mohsen, Meydani
openaire +2 more sources
Angiozyme: A Novel angiogenesis inhibitor
Current Oncology Reports, 2001Several inhibitors of angiogenesis are being developed for the treatment of cancer. One dominant strategy involves disruption of the vascular endothelial growth factor (VEGF) pathway by inhibition of the receptors for VEGF. Inhibition of the VEGF receptor activity can be accomplished using catalytic RNA molecules known as ribozymes, which downregulate ...
D E, Weng, N, Usman
openaire +2 more sources
Maspin is an angiogenesis inhibitor
Nature Medicine, 2000Maspin, a unique member of the serpin family, is a secreted protein encoded by a class II tumor suppressor gene whose downregulation is associated with the development of breast and prostate cancers. Overexpression of maspin in breast tumor cells limits their growth and metastases in vivo.
M, Zhang, O, Volpert, Y H, Shi, N, Bouck
openaire +2 more sources
Clinical translation of angiogenesis inhibitors
Nature Reviews Cancer, 2002Angiogenesis inhibitors are a new class of drugs, for which the general rules involving conventional chemotherapy might not apply. The successful translation of angiogenesis inhibitors to clinical application depends partly on the transfer of expertise from scientists who are familiar with the biology of angiogenesis to clinicians.
Robert, Kerbel, Judah, Folkman
openaire +2 more sources
Thrombosis associated with angiogenesis inhibitors
Best Practice & Research Clinical Haematology, 2009Recent advances in the understanding of the pathogenesis of cancer have led to the introduction of a variety of biological agents with novel mechanisms of action into clinical trials and even into clinical practice. In particular, tumour-associated neoangiogenesis has become a major target for this new class of antineoplastic agents.
Francesca, Elice +3 more
openaire +2 more sources